126 related articles for article (PubMed ID: 9256829)
1. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors.
Kreissman SG; Rackoff W; Lee M; Breitfeld PP
J Pediatr Hematol Oncol; 1997; 19(4):309-12. PubMed ID: 9256829
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
[TBL] [Abstract][Full Text] [Related]
3. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
4. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.
Fennelly D; Schneider J; Spriggs D; Bengala C; Hakes T; Reich L; Barakat R; Curtin J; Moore MA; Hoskins W
J Clin Oncol; 1995 May; 13(5):1160-6. PubMed ID: 7537799
[TBL] [Abstract][Full Text] [Related]
7. A phase I and II trial of dose-intensified cyclophosphamide and GM-CSF in pediatric malignant brain tumors.
Abrahamsen TG; Lange BJ; Packer RJ; Venzon DJ; Allen JC; Craig CE; Patronas NJ; Katz DA; Goldwein JW; DeLaney TF
J Pediatr Hematol Oncol; 1995 May; 17(2):134-9. PubMed ID: 7749762
[TBL] [Abstract][Full Text] [Related]
8. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.
Ozkaynak MF; Matthay K; Cairo M; Harris RE; Feig S; Reynolds CP; Buckley J; Villablanca JG; Seeger RC
J Clin Oncol; 1998 Mar; 16(3):937-44. PubMed ID: 9508176
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group.
McCowage GB; White L; Carpenter P; Lockwood L; Toogood I; Tiedemann K; Shaw PJ
Med Pediatr Oncol; 1997 Aug; 29(2):108-14. PubMed ID: 9180912
[TBL] [Abstract][Full Text] [Related]
10. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
[TBL] [Abstract][Full Text] [Related]
11. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group.
Carpenter PA; White L; McCowage GB; Nayanar V; Toogood I; Shaw PJ; Lockwood L; Tiedemann K
Cancer; 1997 Aug; 80(3):489-96. PubMed ID: 9241083
[TBL] [Abstract][Full Text] [Related]
12. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
Santana VM; Schell MJ; Williams R; Bowman LC; Thompson EI; Brenner MK; Mirro J
Bone Marrow Transplant; 1992 Nov; 10(5):457-62. PubMed ID: 1464010
[TBL] [Abstract][Full Text] [Related]
13. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of sequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies.
Jakacki RI; Jamison C; Heifetz SA; Caldemeyer K; Hanna M; Sender L
Med Pediatr Oncol; 1997 Dec; 29(6):553-9. PubMed ID: 9324343
[TBL] [Abstract][Full Text] [Related]
15. A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors.
Foreman NK; Schissel D; Le T; Strain J; Fleitz J; Quinones R; Giller R
J Neurooncol; 2005 Jan; 71(2):181-7. PubMed ID: 15690136
[TBL] [Abstract][Full Text] [Related]
16. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
Bracho F; Krailo MD; Shen V; Bergeron S; Davenport V; Liu-Mares W; Blazar BR; Panoskaltsis-Mortari A; van de Ven C; Secola R; Ames MM; Reid JM; Reaman GH; Cairo MS
Clin Cancer Res; 2001 Jan; 7(1):58-67. PubMed ID: 11205919
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.
Bowers DC; Aquino VM; Leavey PJ; Bash RO; Journeycake JM; Tomlinson G; Mulne AF; Haynes HJ; Winick NJ
Pediatr Blood Cancer; 2004 Jan; 42(1):93-8. PubMed ID: 14752800
[TBL] [Abstract][Full Text] [Related]
18. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
Saylors RL; Stewart CF; Zamboni WC; Wall DA; Bell B; Stine KC; Vietti TJ
J Clin Oncol; 1998 Mar; 16(3):945-52. PubMed ID: 9508177
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.
Recchia F; De Filippis S; Torchio P; Rea S; Gulino A; Quaglino D; Frati L
Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
